A Study of the Long-Term Safety of Tafamidis for Patients with Transthyretin Cardiomyopathy

Overview

About this study

The purpose of this study is to evaluate the long-term safety of tafamidis meglumine for treating patients who have either the genetic variants or wild-type transthyretin, resulting in amyloid heart muscle disease.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Completion of 30 months of study treatment on Pfizer Protocol B3461028.

Exclusion Criteria:

  • Liver and/or heart transplant, or an implanted cardiac mechanical assist device.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Rochester, Minn.

Mayo Clinic principal investigator

Martha Grogan, M.D.

Closed for enrollment

More information

Publications

Publications are currently not available
.
CLS-20258090

Mayo Clinic Footer